The ACORN Study: Nephrotoxoicity in Antibiotics

CEimpact Podcast

Piperacillin/tazobactam and vancomycin have been reported in numerous clinical trials to be associated with acute kidney injury. Comparatively, cefepime with vancomycin may increase neurotoxic effects. Join host, Geoff Wall, as he evaluates a new randomized controlled trial evaluating the safety of these medications.
The GameChanger
Vancomycin, even at appropriate doses, can cause nephrotoxicity. Piperacillin/tazobactam does not seem to increase the risk of adverse kidney outcomes. However, cefepime is associated with an increased risk of neurologic toxicity.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Tong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA. 2023;330(16):1531–1533. doi:10.1001/jama.2023.18591
https://jamanetwork.com/journals/jama/fullarticle/2810593

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the risk of nephrotoxicity with piperacillin/tazobactam
2. Discuss the factors that exacerbate neurologic adverse effects with cefepime
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-353-H01-P
Initial release date: 11/13/2023
Expiration date: 11/13/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram